buprenorphine hydrochloride - Profile

What are the generic drug sources for buprenorphine hydrochloride and what is the scope of patent protection?

Buprenorphine hydrochloride is the generic ingredient in ten branded drugs marketed by Bdsi, Reacx Pharms, Indivior, Am Regent, Hikma, Hospira, Ph Health, Somerset Theraps Llc, Actavis Elizabeth, Ascent Pharms Inc, Barr, Ethypharm, Pharmobedient, Rhodes Pharms, Rubicon Research, Specgx Llc, Sun Pharm, Alvogen, Difgen Pharms, Dr Reddys Labs Sa, Mylan Technologies, Teva Pharms Usa, Alkem Labs Ltd, Amneal Pharms, Lannett Co Inc, Wes Pharma Inc, and Edenbridge Pharms, and is included in forty-four NDAs. There are eighteen patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Buprenorphine hydrochloride has seventy-six patent family members in twenty-seven countries.

There are two tentative approvals for this compound.

Summary for buprenorphine hydrochloride

International Patents:	76
US Patents:	18
Tradenames:	10
Applicants:	27
NDAs:	44
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for buprenorphine hydrochloride

Generic filers with tentative approvals for BUPRENORPHINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		EQ 8MG BASE;EQ 2MG BASE	FILM;BUCCAL, SUBLINGUAL
		EQ 8.6MG BASE;EQ 2.1MG BASE	TABLET;SUBLINGUAL
		EQ 5.7MG BASE;EQ 1.4MG BASE	TABLET;SUBLINGUAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for BUPRENORPHINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BELBUCA	Buccal Film	buprenorphine hydrochloride	75 mcg and 150 mcg	207932	1	2016-10-24
BELBUCA	Buccal Film	buprenorphine hydrochloride	300 mcg, 450 mcg, 600 mcg and 750 mcg	207932	1	2016-10-04
BELBUCA	Buccal Film	buprenorphine hydrochloride	900 mcg	207932	1	2016-09-12

US Patents and Regulatory Information for buprenorphine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-001	Oct 23, 2015		RX	Yes	No			Y
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-001	Oct 23, 2015		RX	Yes	No
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-001	Oct 23, 2015		RX	Yes	No			Y
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-002	Oct 23, 2015		RX	Yes	No
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-002	Oct 23, 2015		RX	Yes	No			Y

Expired US Patents for buprenorphine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-003	Oct 23, 2015
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-007	Oct 23, 2015
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-001	Oct 23, 2015
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-005	Oct 23, 2015
Bdsi	BELBUCA	buprenorphine hydrochloride	FILM;BUCCAL	207932-005	Oct 23, 2015

International Patents for buprenorphine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Mexico	2009000745	DISPOSITIVOS DE SUMINISTRO TRANSMUCOSA CON ADMISION MEJORADA. (TRANSMUCOSAL DELIVERY DEVICES WITH ENHANCED UPTAKE.)
South Korea	20090033903
Australia	2019202602	Transmucosal drug delivery devices for use in chronic pain relief
Brazil	122020000250
Norway	20200273

Buprenorphine Hydrochloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Buprenorphine hydrochloride (HCl) is a semi-synthetic opioid primarily used in opioid addiction treatment and pain management. Its unique pharmacological profile, including high affinity for μ-opioid receptors and partial agonist activity, positions it favorably amid the ongoing opioid crisis and expanding pain management needs. The global market for buprenorphine is projected to grow at a compound annual growth rate (CAGR) of approximately 7.5% through 2030. Major market drivers include rising opioid addiction prevalence, increasing reliance on outpatient treatment protocols, and supportive regulatory policies. Key investment considerations involve patent expirations, competitive landscape, regulatory pathways, and manufacturing complexities.

---

1. Market Overview and Current Landscape

Parameter	Detail
Global Market Value (2022)	~$4.2 billion (Grand View Research) [1]
Projected CAGR (2023–2030)	7.5%
Key Applications	Opioid dependence treatment, pain management
Leading Regions	North America, Europe, Asia-Pacific

Top Market Players:

• Indivior Plc.
• Mylan/NantHealth
• AstraZeneca
• Teva Pharmaceuticals
• Sandoz (Novartis)

Demand is anchored by established patents and regulatory approvals, with Generation 3 formulations (e.g., implantable device, buprenorphine patches) emerging to expand treatment options.

---

2. Market Drivers and Constraints

Drivers	Impact	Constraints	Impact
Rising opioid addiction	Expands demand for substitution therapies	Stringent regulatory approval	Lengthy approval processes
Shift towards outpatient treatment	Increases demand for oral/subcutaneous formulations	Patent expirations leading to generic biosimilars	Market erosion risks
Supportive health policies	Insurance coverage and subsidy programs	Abuse potential and diversion	Necessitates robust formulation controls
Growing geriatric population	Enhanced pain management needs	Supply chain complexities	Increased manufacturing costs

---

3. Regulatory and Patent Landscape

Patent Status	Impact	Key Regulations	Region-specific Notes
Patents expiring (US: 2028-2032)	Potential for generics; market share shifts	FDA & EMA approvals, REMS programs	Generics may reduce prices by 30–50%
New formulations (e.g., implants, patches)	Market expansion, premium pricing	Fast-track approvals in certain regions	Innovation helps defend against generics
Regulatory hurdles	Slows product launch; increases R&D costs	Stringent safety and abuse-deterrent standards	Impact on market entry timing

---

4. Investment Opportunities

Source of Investment	Type	Considerations
Patent-backed branded drugs	High margins, regulatory exclusivity	Patent expiry risks, market saturation
Generic formulations	Lower development cost, high volume	Price erosion, competitive entry barriers
Novel delivery systems (e.g., implants)	Premium pricing, less competition	R&D intensity, regulatory approval pathway
Contract manufacturing and API supply	Cost-effective entry points	Supply chain reliability, quality standards

---

5. Financial Trajectory and Revenue Projections

Scenario	2023 ($B)	2025 ($B)	2030 ($B)
Conservative	4.5	6.0	10.0
Moderate	4.8	7.2	12.5
Aggressive	5.0	8.0	15.0

Assumptions: Steady growth fueled by increased adoption, generic market penetration post-patent expiry, and new formulation launches.

6. Investment Risks and Challenges

• Patent Cliff: Major patents expiring within next 5 years could substantially erode margins.
• Regulatory Delays: Mishandling abuse-deterrent formulations or new delivery systems can delay market entry.
• Market Saturation: High penetration in mature markets reduces room for robust growth.
• Diversion and Abuse: Ongoing concerns necessitate investment in abuse-deterrent formulations, which may increase costs and development timelines.
• Pricing Pressures: Payers and government agencies’ push for lower-cost generics impact profitability.

---

7. Competitive Landscape Comparison

Company	Product Portfolio	Market Share (Est.)	Key Strengths
Indivior Plc	Suboxone, Sublocade	~50%	Strong brand recognition; integrated delivery systems
Mylan/NantHealth	Generic buprenorphine formulations	20–30%	Cost leadership; broad portfolio
AstraZeneca	Buprenorphine patches	Niche market	Innovation in delivery technologies
Teva & Sandoz	Generics	variable	Cost efficiency; global footprint

---

8. Comparative Analysis: Buprenorphine vs. Related Drugs

Parameter	Buprenorphine Hydrochloride	Methadone	Naltrexone
Indications	Opioid dependence, pain	Opioid dependence, pain	Opioid dependence, AUD
Abuse Potential	Moderate, with abuse-deterrent formulations	High	Low
Market Growth	7.5% CAGR	~4%	~3.5%
Regulatory Status	Approved in 100+ countries	Global	Widely approved, OTC in some regions

---

9. Policy and Reimbursement Trends

Region	Policy Direction	Reimbursement Trends	Implication
United States	Expansion of Medicaid coverage, REMS programs	Favorable for branded and generic drugs	Increased patient access
European Union	EMA support for opioid addiction therapies	Generally reimburse drugs with evidence	Market access facilitated
Asia-Pacific	Growing awareness, national programs	Variable; emerging markets	High growth potential

---

10. Deep Dive: Emerging Formulations and Technologies

Innovation	Advantages	Development Stage	Potential Impact
Depot injections and implants	Enhanced compliance, abuse deterrence	Clinical trials ongoing	Capture premium segment
Transdermal patches	Bypass hepatic first-pass, steady plasma levels	Approved and in expansion	Market differentiation
Abuse-deterrent formulations	Reduce diversion, improve safety	Regulatory approval in US	Support premium pricing

---

Conclusion

Investment prospects for buprenorphine hydrochloride are favorable driven by ongoing opioid crises, expanding indication profiles, and pipeline innovations. While patent expiries pose challenges, emerging formulations and strategic regional expansion offer avenues for sustained growth. Key risks include regulatory delays, market saturation, and societal concerns over abuse potential. Investors should focus on companies with diversified portfolios, strong R&D pipelines, and capacity for regulatory navigation.

---

Key Takeaways

• The global buprenorphine market is expected to grow at 7.5% CAGR until 2030, driven mainly by opioid dependency treatment needs.
• Patent expiries from 2028 onward will create opportunities for generic entrants and price reductions.
• Innovative delivery systems (e.g., implants, patches) are critical for maintaining market differentiation.
• Regulatory policies and reimbursement strategies significantly influence market access and profitability.
• Market entry risks include regulatory hurdles, diversion concerns, and competitive pressures, but pipelined formulations mitigate some risks.
• Regional dynamics vary, with North America and Europe leading and Asia-Pacific presenting high growth potential.

---

FAQs

Q1: How will patent expirations influence the buprenorphine market?
Patent expirations projected between 2028 and 2032 are likely to reduce branded drug prices by 30-50%, increasing generic market share, pressuring margins, but also creating opportunities for new formulations and formulations with abuse-deterrent features.

Q2: What are the primary drivers for growth in buprenorphine formulations?
Rising opioid addiction, shift to outpatient treatment, development of abuse-deterrent formulations, and innovative delivery mechanisms are key drivers.

Q3: How significant are regulatory hurdles for new buprenorphine formulations?
Regulatory barriers are substantial, especially for abuse-deterrent and implantable forms, requiring extensive clinical data and compliance with safety standards, which can lead to delays and increased R&D costs.

Q4: Which regions offer the most lucrative investment opportunities?
North America remains the primary market due to high prevalence and established healthcare infrastructure; Asia-Pacific offers growth potential due to increasing awareness and expanding healthcare access.

Q5: What are the major risks associated with investing in buprenorphine products?
Patent cliffs, regulatory delays, societal concerns about abuse, market saturation, and price competition from generics constitute primary risks. Mitigating strategies involve focusing on pipeline innovation and regional expansion.

---

References

[1] Grand View Research. Buprenorphine Market Size, Share & Trends Analysis Report (2022).
[2] IQVIA. Opioid Dependence Therapy Market Report (2022).
[3] U.S. Food and Drug Administration. Guidelines on Abuse-Deterrent Formulations (2021).
[4] MarketWatch. Pharmaceutical Industry Outlook 2023–2030.
[5] European Medicines Agency. Regulatory pathways for opioid addiction treatments (2022).